Sirois M G, Jancar S, Braquet P, Plante G E, Sirois P
Department of Pharmacology, Faculty of Medicine, University of Sherbrooke, P.Q., Canada.
Prostaglandins. 1988 Nov;36(5):631-44. doi: 10.1016/0090-6980(88)90009-3.
The effect of the potent inflammatory mediator, platelet activating factor (PAF) was studied on the vascular permeability of selected rat tissues using the extravasation of Evans blue dye (EB) as a marker. EB (20 mg/kg) was injected in the caudal vein together with increasing doses of PAF (0.1, 1.0 and 5.0 micrograms/kg). The animals were killed and the dye was extracted in selected organs using formamide (4 ml/g wet weight tissues) and the content was expressed as EB micrograms/g dry weight. Extravasation of EB varied markedly from one tissue to another and increased as a function of time (from 0 to 60 min). PAF (5.0 micrograms/kg) increased the pancreas and duodenum vascular permeability by 15 and 5 fold respectively. At the doses of 0.1 and 1.0 microgram/kg, PAF induced a slight increase (P less than 0.01) of the vascular permeability of the heart 5 min after the injection. The PAF antagonist BN-52021 (2 and 10 mg/kg) produced a dose-dependent inhibition of the PAF effects on the pancreas, heart and duodenum. Maximum inhibition (approximately 100%) was achieved at the dose of 10 mg/kg. This antagonist given in the absence or the presence of PAF reduced the lung plasma extravasation below control levels. A thromboxane antagonist, L-655,240 (1.0 and 5.0 mg/kg) also inhibited PAF-induced increases in vascular permeability in heart, duodenum and pancreas. It also reduced below control levels the EB extravasation in kidneys, spleen and lungs. Maximum inhibition (50% for the duodenum, and 40% for the pancreas) was achieved at the dose of 5.0 mg/kg.
以伊文思蓝染料(EB)外渗作为标志物,研究了强效炎症介质血小板活化因子(PAF)对特定大鼠组织血管通透性的影响。将EB(20mg/kg)与递增剂量的PAF(0.1、1.0和5.0微克/千克)一起经尾静脉注射。处死动物后,使用甲酰胺(4ml/g湿重组织)从选定器官中提取染料,其含量以EB微克/克干重表示。EB的外渗在不同组织间差异显著,并随时间(从0到60分钟)而增加。PAF(5.0微克/千克)分别使胰腺和十二指肠的血管通透性增加了15倍和5倍。在0.1和1.0微克/千克的剂量下,PAF在注射后5分钟使心脏的血管通透性略有增加(P<0.01)。PAF拮抗剂BN - 52021(2和10mg/kg)对PAF对胰腺、心脏和十二指肠的作用产生剂量依赖性抑制。在10mg/kg的剂量下达到最大抑制(约100%)。在不存在或存在PAF的情况下给予该拮抗剂,均可使肺血浆外渗降至对照水平以下。血栓素拮抗剂L - 655,240(1.0和5.0mg/kg)也抑制PAF诱导的心脏、十二指肠和胰腺血管通透性增加。它还使肾脏、脾脏和肺中的EB外渗降至对照水平以下。在5.0mg/kg的剂量下达到最大抑制(十二指肠为50%,胰腺为40%)。